Cell therapy biotech Longeveron prices IPO at $10 low end - (NASDAQ via NewsPoints Desk)

  • Longeveron has raised $27 million by offering 2.7 million shares at $10 in an initial public offering, as reported in NASDAQ.

  • The company’s lead product, LOMECEL-B, is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

  • Longeveron is currently sponsoring Phase I and II trials in aging frailty, Alzheimer’s disease, the metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

To read more NewsPoints articles, click here.